Former unicorn genetics startup Human Longevity loses its horn
The company's valuation has declined 80 percent, from a $1.6 billion peak to $310 million, according to The Wall Street Journal.
The company's valuation has declined 80 percent, from a $1.6 billion peak to $310 million, according to The Wall Street Journal.
Genomic sequencing legend Craig Venter now stands accused of stealing trade secrets and attempting to poach employees by the very company he founded.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
J. Craig Venter will step down as CEO of his ambitious genomics-driven biotech Human Longevity, effective January 9.